PLX Protalix BioTherapeutics Inc. (DE)

2.45
-0.02  -1%
Previous Close 2.47
Open 2.55
Price To Book -1.13
Market Cap 79,484,458
Shares 32,442,636
Volume 114,422
Short Ratio 4.29
Av. Daily Volume 116,741
Stock charts supplied by TradingView

NewsSee all news

  1. Protalix BioTherapeutics Announces Closing of $43.7 Million Private Placement

    CARMIEL, Israel, March 18, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE:PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic

  2. Protalix Biotherapeutics Announces Feasibility Study with Kirin Holdings on the Production of a Novel Complex Protein

    CARMIEL, Israel, March 16, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE:PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic

  3. Protalix BioTherapeutics Reports Fourth Quarter and Full Year 2019 Financial and Business Results

    CARMIEL, Israel, March 12, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE:PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant

  4. Protalix BioTherapeutics Announces $43.7 Million in Financing to Further Advance its Programs in Fabry Disease

    CARMIEL, Israel, March 12, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE:PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic

  5. Protalix BioTherapeutics to Hold Fourth Quarter and Full-Year 2019 Financial and Business Results Conference Call on March 12, 2020

    CARMIEL, Israel, March 5, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE:PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Approved May 1, 2012.
Taliglucerase alfa
Gaucher disease
Phase 3 completion of enrolment announced September 24, 2019.
Pegunigalsidase alfa (PRX-102) - BALANCE
Fabry disease
Phase 2 interim data released January 3, 2017. Full data released April 12, 2017. Company noted data were positive but results showed efficacy down on January data.
AIR DNase (PRX-110)
Cystic Fibrosis
Phase 2 data released March 13, 2018 - key endpoints met. Data presented at DDW Meeting - 67% of patients experienced a clinical response.
OPRX-106
Ulcerative Colitis
BLA filing due 2Q 2020.
Pegunigalsidase alfa (PRX-102)
Fabry disease
Phase 3 completion of enrolment announced June 17, 2019.
Pegunigalsidase alfa (PRX-102) - BRIGHT
Fabry disease

Latest News

  1. Protalix BioTherapeutics Announces Closing of $43.7 Million Private Placement

    CARMIEL, Israel, March 18, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE:PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic

  2. Protalix Biotherapeutics Announces Feasibility Study with Kirin Holdings on the Production of a Novel Complex Protein

    CARMIEL, Israel, March 16, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE:PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic

  3. Protalix BioTherapeutics Reports Fourth Quarter and Full Year 2019 Financial and Business Results

    CARMIEL, Israel, March 12, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE:PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant

  4. Protalix BioTherapeutics Announces $43.7 Million in Financing to Further Advance its Programs in Fabry Disease

    CARMIEL, Israel, March 12, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE:PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic

  5. Protalix BioTherapeutics to Hold Fourth Quarter and Full-Year 2019 Financial and Business Results Conference Call on March 12, 2020

    CARMIEL, Israel, March 5, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE:PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic

  6. Protalix BioTherapeutics Presents Key Clinical Data of Pegunigalsidase Alfa for the Treatment of Fabry Disease at the 16th Annual WORLDSymposium™ 2020

    CARMIEL, Israel, Feb. 10, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE:PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic

  7. Protalix BioTherapeutics and Chiesi Farmaceutici Announce Receipt of "Agreement Letter" for Initial Pediatric Study Plan for PRX-102 for the Treatment of Fabry Disease

    CARMIEL, Israel, Feb. 6, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE:PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant

  8. Protalix BioTherapeutics to Participate in the 2020 BIO CEO & Investor Conference and the Noble Capital Markets' 16th Annual Small & Microcap Investor Conference

    CARMIEL, Israel, Feb. 4, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE:PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic

  9. Protalix BioTherapeutics to Participate in the 16th Annual WORLDSymposium™ 2020

    CARMIEL, Israel, Jan. 30, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE:PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant

  10. Protalix BioTherapeutics Adds Two Accomplished Biopharmaceutical Executives to its Board of Directors

    CARMIEL, Israel, Dec. 19, 2019 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE:PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic

  11. Protalix BioTherapeutics Announces 1-for-10 Reverse Stock Split

    CARMIEL, Israel, Dec. 9, 2019 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE:PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic

  12. Protalix BioTherapeutics Hosting Key Opinion Leader Meeting on PRX‑102 Drug Candidate for the Treatment of Fabry Disease

    CARMIEL, Israel, Nov. 27, 2019 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE:PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic

  13. Protalix BioTherapeutics and Chiesi Farmaceutici Announce Successful pre-BLA Meeting with FDA for Accelerated Approval of pegunigalsidase alfa for the Treatment of Fabry Disease in the United States

    CARMIEL, Israel, Nov. 18, 2019 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE:PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic

  14. Protalix BioTherapeutics Reports Third Quarter 2019 Results and Provides Corporate Update

    CARMIEL, Israel, Nov. 7, 2019 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE:PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic

  15. Protalix BioTherapeutics and Chiesi Group Complete Enrollment in the Third Phase III Clinical Trial of pegunigalsidase alfa (PRX‑102) for the Treatment of Fabry Disease

    CARMIEL, Israel, Sept. 24, 2019 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE:PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic

  16. Protalix BioTherapeutics and Chiesi Group Complete Enrollment in the Third Phase III Clinical Trial of pegunigalsidase alfa (PRX‑102) for the Treatment of Fabry Disease

    CARMIEL, Israel, Sept. 24, 2019 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE:PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic

  17. Protalix BioTherapeutics Receives Listing Deficiency Letter from NYSE American

    CARMIEL, Israel, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins

  18. Protalix BioTherapeutics Focuses on Evaluating and Pursuing Alternatives to Maximize Shareholder Value through Refinancing & Strategic Partnerships

    CARMIEL, Israel, Aug. 22, 2019 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE:PLX) (TASE: PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins